U-Act-After: An Observational Study on Long-Term Efficacy of Tight Control RoActemra/Actemra (Tocilizumab) and/or Methotrexate in Patients With Early Rheumatoid Arthritis Who Have Participated in the U-Act-Early Study (ML22497)
NCT ID: NCT01918267
Last Updated: 2018-05-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
226 participants
OBSERVATIONAL
2012-04-10
2017-10-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis
NCT01034137
An Observational Study on Long-Term Efficacy and Safety of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (FAct)
NCT01483326
A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy
NCT01705730
An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)
NCT01384461
A Retrospective, Observational Study of RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis
NCT01921478
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must be willing to give written informed consent
Exclusion Criteria
* Patients who are drop-outs in the U-Act-Early trial due to withdrawal of consent, are lost to follow-up or are serious protocol violators
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medisch Centrum Alkmaar
Alkmaar, , Netherlands
Meander Medisch Centrum; Locatie Lichtenberg
Amersfoort, , Netherlands
Gelre Ziekenhuis Apeldoorn, Lokatie Lukas; Afdeling Interne Geneeskunde
Apeldoorn, , Netherlands
Amphia Ziekenhuis
Breda, , Netherlands
Rivas Zorggroep, Locatie Beatrixziekenhuis; Reumatologie
Gorinchem, , Netherlands
Groene Hart Ziekenhuis
Gouda, , Netherlands
Universitair Medisch Centrum Groningen; Department of Rheumatology
Groningen, , Netherlands
Kennemer Gasthuis; Inwendige Geneeskunde
Haarlem, , Netherlands
Atrium Medisch Centrum; Nephrology
Heerlen, , Netherlands
Tergooiziekenhuizen, loc. Hilversum
Hilversum, , Netherlands
Spaarne Ziekenhuis; Inwendige Geneeskunde
Hoofddorp, , Netherlands
Medisch Centrum Leeuwarden; Reumatology
Leeuwarden, , Netherlands
Academisch Ziekenhuis Leiden; Dept of Rheumatology
Leiden, , Netherlands
Ijsselmeer Ziekenhuizen; Interne Geneeskunde
Lelystad, , Netherlands
St. Antonius Ziekenhuis Nieuwegein
Nieuwegein, , Netherlands
St. Maartenskliniek
Nijmegen, , Netherlands
Antonius Ziekenhuis Sneek; Department of Rheumatology
Sneek, , Netherlands
University Medical Centre Utrecht; Reumatologie en Klinische Immunologie
Utrecht, , Netherlands
Maartenskliniek Woerden
Woerden, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML28388
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.